• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Onconetix Inc.

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCO alert in real time by email
    SC 13G 1 ss4101599_sc13g.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     



     

    Onconetix, Inc.
    (Name of Issuer)

     

     

    Common stock, par value $0.00001 per share
    (Title of Class of Securities)

     

    68237Q104

    (CUSIP Number)

     

    September 24, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       

     

     

             
    1

    NAME OF REPORTING PERSONS

     Zurcher Kantonalbank

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Switzerland

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    562,691

    6 SHARED VOTING POWER
    7

    SOLE DISPOSITIVE POWER

     

     562,691

    8

    SHARED DISPOSITIVE POWER

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    562,691

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.8%

    12

    TYPE OF REPORTING PERSON

     FI

     

     

       

     

     

     

    Item 1.   (a) Name of Issuer:
        Onconetix, Inc.

     

        (b) Address of Issuer’s Principal Executive Offices:

    201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202

     

    Item 2.   (a) Name of Person Filing:

    Zurcher Kantonalbank

        (b) Address of Principal Business Office:

    BAHNHOFSTRASSE 9

    ZURICH, SWITZERLAND 8001

        (c) Citizenship:

    Switzerland

        (d) Title of Class of Securities:

    Common stock, par value $0.00001 per share

        (e) CUSIP No.:

             68237Q104

     

    Item 3.      

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)

     

    Item 4. Ownership:

    Ownership as of September 30, 2024 is incorporated by reference to items (5) – (9) and (11) of the cover page.

    Item 5. Ownership of Five Percent or Less of a Class.

    Not Applicable

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group.

     Not Applicable

     

     

    Item 9. Notice of Dissolution of Group.

     Not Applicable

       

     

     

     

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

       

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

       
           
      By: /s/ Matthias Nänni
        Name: Matthias Nänni
        Title: Senior Member of Management

     

     

       

     

     

     

    Get the next $ONCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

      Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a Staff delisting letter from The Nasdaq Capital Market ("Nasdaq") on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the "10-Q") is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange C

      5/22/25 4:50:00 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

      Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a Staff delisting letter from The Nasdaq Capital Market ("Nasdaq") on April 24, 2025 indicating that the Company's failure to file its Annual Report on Form 10-K for the fiscal year ended December 30, 2024 is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule").   This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.  As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission

      4/30/25 6:13:39 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.

      CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex. Andrew J. Oakley, Chairman of the Board of Onconetix, stated, "We are excited about the opportunity to combine forces with Ocuvex, whose pipeline of commercial and late c

      4/8/25 8:30:00 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Oakley Andrew John was granted 1,709 shares (SEC Form 4)

      4 - Onconetix, Inc. (0001782107) (Issuer)

      3/25/25 3:44:38 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Oakley Andrew John

      3 - Onconetix, Inc. (0001782107) (Issuer)

      3/7/25 6:07:11 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Interim CEO, CSO Schiess Ralph was granted 177,462 shares, increasing direct ownership by 36% to 673,365 units (SEC Form 4)

      4 - Onconetix, Inc. (0001782107) (Issuer)

      1/22/25 4:15:13 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    SEC Filings

    See more
    • Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Onconetix, Inc. (0001782107) (Filer)

      5/22/25 5:10:57 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Onconetix, Inc. (0001782107) (Filer)

      4/30/25 5:23:53 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Onconetix Inc.

      DEF 14A - Onconetix, Inc. (0001782107) (Filer)

      4/29/25 6:50:09 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Onconetix Inc.

      SC 13G - Onconetix, Inc. (0001782107) (Subject)

      11/14/24 11:19:35 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Onconetix Inc.

      SC 13D - Onconetix, Inc. (0001782107) (Subject)

      10/1/24 4:35:03 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Onconetix Inc.

      SC 13D - Onconetix, Inc. (0001782107) (Subject)

      10/1/24 4:35:03 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care